Based on the positive results, an antisense oligonucleotide targeting c-Myb transcript has been developed as a targeted therapeutic and a Phase I clinical trial begun for patients with advanced hematologic malignancies (National Clinical Trials Identifier: NCT00780052). This evidence concerns the gene MYB and hematologic disorder.